Download PDF
Arzneimittelforschung 2008; 58(10): 501-504
DOI: 10.1055/s-0031-1296548
CNS-active Drugs · Hypnotics · Psychotropics · Sedatives
Editio Cantor Verlag Aulendorf (Germany)

Comparative Bioavailability of Two Estazolam Tablet Formulations in Indonesian Healthy Volunteers

Yahdiana Harahap
1   Department of Pharmacy, Faculty of Mathematic and Science, University of Indonesia, Depok, Indonesia
,
Lucy Sasongko
2   School of Pharmacy, Bandung Institute of Technology, Bandung, Indonesia
,
Budi Prasaja
3   PT. Clinisindo Laboratories, Jakarta, Indonesia
,
Ega Indriati
3   PT. Clinisindo Laboratories, Jakarta, Indonesia
,
Windy Lusthom
3   PT. Clinisindo Laboratories, Jakarta, Indonesia
,
L Lipin
3   PT. Clinisindo Laboratories, Jakarta, Indonesia
› Author Affiliations
Further Information

Publication History

Publication Date:
19 December 2011 (online)

    Permissions and Reprints

Abstract

Aim:

To compare the bioavailability of two estazolam (CAS 29975-16-4) tablet formulations (Estalin® 2 mg tablets as test formulation and 2 mg tablets of the originator product as reference formulation).

Methods:

The study was conducted according to an open label, randomized two-way cross-over design with a two-week washout period. Twenty-four subjects received each of the two estazolam formulations. Blood samples for pharmacokinetic profiling were taken up to 72 h after drug administration in fasting condition. Plasma concentrations of estazolam were determined with a validated HPLC method with ultraviolet detection. Pharmacokinetic parameters were calculated from observed plasma concentration-time profiles.

Results:

The mean AUC0–t, AUC0–∞ and Cmax were 2581.38 ng • h/mL, 2934.37 ng • h/mL and 95.25 ng/mL, respectively for the test formulation and 2835.75 ng • h/mL, 3207.73 ng • h/mL and 99.32 ng/mL, respectively, for the reference formulation. The median Tmax for both formulations was 1 h. The point estimates and 90% confidence intervals for AUC0–t, AUC0–∞ and Cmax were 91.03% (87.48–94.72%), 91.48% (86.67–96.55%) and 95.90% (92.60–99.31%) respectively, satisfying the bioequivalence criteria of the European Committee for Proprietary Medicinal Products and the US Food and Drug Administration guidelines.

Conclusion:

These results indicate that two formulations of estazolam are bioequivalent and, thus, may be prescribed interchangeably.

Key words

Benzodiazepines - CAS 29975-16-4, - Estalin® - Estazolam, bioequivalence, pharmacokinetics - Hypnotics - Sedatives
 

  • References

  • 1 Dingemanse J. Pharmacotherapy of insomnia: practice and prospects. Pharm World Sci. 1995; 17 (3) 67-75
    CrossrefPubMedGoogle Scholar
  • 2 Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician. 2007; 76 (4) 517-526
    PubMedGoogle Scholar
  • 3 Machinist JM, Bopp BA, Anderson DJ, Granneman GR, Sonders RC, Tolman K et al. Metabolism of 14C-estazolam in dogs and humans. Xenobiotica. 1986; 16 (1) 11-20
    CrossrefPubMedGoogle Scholar
  • 4 Mancinelli A, Guiso G, Garattini S, Urso R, Caccia S. Kinetic and pharmacological studies on estazolam in mice and man. Xenobiotica. 1985; 15 (3) 257-265
    CrossrefPubMedGoogle Scholar
  • 5 Gustavson LE, Carrigan PJ. The clinical pharmacokinetics of single dose of estazolam. Am J Med. 1990; 88 (3A) 2S-5S
    PubMedGoogle Scholar
  • 6 Dal Bo L, Verga F, Marzo A, La Commare P, De Vito ML. Gas chromatographic assay for estazolam in human plasma and results of a bioequivalence study. Pharmacol Res. 1997; 3 (4) 329-333
    PubMedGoogle Scholar
  • 7 CPMP Committee for Proprietary Medicinal Products. Note for guidance on investigation of bioavailability and bioequivalence. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. 2001 (CPMP/EWP/QWP/1401/98).
    PubMed
  • 8 Diletti E, Hauschke D, Stenijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int] Clin Ther Toxicol. 1991; 29: 1-8
    PubMedGoogle Scholar